|Targets||PKC | PKA|
|Description||H-9 dihydrochloride is a protein kinase inhibitor. It inhibits PKA (Ki = 1.9 μM), PKG (Ki = 0.9 μM), CaMK II (Ki = 60 μM), PKC (Ki = 18 μM), casein kinase I (Ki = 110 μ M) and casein kinase II (Ki > 300 μM). H-9 hydrochloride reduces the cAMP-mediated excitatory response to serotonin in C. elegans enteric neurons2 and inhibits PKA-mediated phosphorylation in a rat seizure model.|
|Brife Description||protein kinase inhibitor|
|Purity||≥99% by HPLC|
|Related CAS||84468-17-7 (free base)|
|Synonyms||H-9 dihydrochloride; H 9 dihydrochloride; H9 dihydrochloride; N-(2-Aminoethyl)-5-isoquinolinesulfonamide dihydrochloride|
PKI 14-22 amide, myristoylated
PKI 14-22 amide, myristoylated is a cell-permeable version of protein kinase inhibitor PKI (14-22) amide. N-terminus is myristoylated to increase cell membrane ...
Ruboxistaurin, also called as LY 333531, initially developed for the treatment of diabetic retinopathy, inhibits isolated enzymes PKCβI and PKCβII with a half-m...
Ro 31-8220 Mesylate
Ro 31-8220 inhibits rat brain PKC activity with IC50 of 23 nM, and does not show any high degree of selectivity between PKC-α, PKC-β, PKC-γ, and PKC-ε.
KT 5720, an anti-bacterial agent synthesized by the fungus Nocardiopsis sp, specificly blocks PKA signaling through competitive inhibition of ATP with a Ki valu...
LY 333531 mesylate
LY 333531 mesylate is an orally-available protein kinase C β (PKC-β) specific inhibitor used for the treatment of diabetic nephropathy and diabetic macular edem...
PKI (5-24) is a competitive, non-reversible peptide inhibitor of PKA (cAMP-dependent protein kinase) (Ki = 2.3 nM). Its sequence is derived from the heat-stable...
[Glu27]-PKC (19-36) is the inactive single mutation control peptide for PKC (19-36), a pseudosubstrate peptide inhibitor of protein kinase C.
H-9 dihydrochloride is a protein kinase inhibitor. It inhibits PKA (Ki = 1.9 μM), PKG (Ki = 0.9 μM), CaMK II (Ki = 60 μM), PKC (Ki = 18 μM), casein kinase I (Ki...